Join us on Wednesday, February 1^st for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Wednesday, February 1, 2023
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Module 1: Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
• Module 2: Follicular Lymphoma and Mantle Cell Lymphoma

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of Hodgkin and non-Hodgkin lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand published research informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
• Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential use of those therapies in clinical practice.
• Consider patient age, performance status and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
• Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
• Assess available clinical trial findings informing the use of CD19-directed CAR (chimeric antigen receptor) T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients regarding the potential benefits of this therapeutic strategy.
• Recall new data with agents and strategies currently under investigation for HL and various forms of non-Hodgkin lymphoma, and consider the potential role of these agents in treatment regimens in addition to ongoing trial opportunities for eligible patients.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Flowers — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Curio Science, Denovo Biopharma, Epizyme Inc, Foresight Diagnostics, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Janssen Biotech Inc, MEI Pharma Inc, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Seagen Inc; Research Funding: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Celgene Corporation, Cellectis, Eastern Cooperative Oncology Group, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, National Cancer Institute, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, The V Foundation for Cancer Research, Xencor, ZIOPHARM Oncology Inc. Dr Sehn — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Genentech, a member of the Roche Group, Teva Oncology.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Incyte Corporation, Karyopharm Therapeutics, and Seagen Inc.